<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367965</url>
  </required_header>
  <id_info>
    <org_study_id>190-055</org_study_id>
    <nct_id>NCT00367965</nct_id>
  </id_info>
  <brief_title>Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis</brief_title>
  <official_title>The Effect of Eszopiclone 3 mg Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate subjective sleep efficacy of eszopiclone 3 mg in subjects with insomnia
      related to rheumatoid arthritis (RA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, randomized, double-blind, placebo controlled, parallel group study of
      eszopiclone 3 mg in subjects with insomnia related to rheumatoid arthritis. This study was
      previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon
      Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion
      Pharmaceuticals Inc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean subjective wake time after sleep onset (WASO)</measure>
    <time_frame>Week 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>WASO</measure>
    <time_frame>Weeks 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of nocturnal awakening</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total sleep time (TST)</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Efficiency</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep latency (SL) in subjects with sleep latency of 30 minutes or greater at screening</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of sleep</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of sleep</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime alertness</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to concentrate</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical well-being</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to function</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of rebound insomnia and withdrawal effects will be assessed for WASO, and TST as well as for SL in subjects with sleep latency of 30 minutes or greater at screening</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of morning stiffness</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain severity (from IVRS)</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arthritis Self-Efficacy Scale</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Clinical Global Impression of treatment</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR Response Criteria</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with increase in dose or new prescription of pain medications</measure>
    <time_frame>Weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with increase in dose or new prescription of disease modifying medications</measure>
    <time_frame>Weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Insomnia</condition>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eszopiclone 3 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eszopiclone</intervention_name>
    <description>eszopiclone 3 mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lunesta</other_name>
    <other_name>S-zopiclone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subject must understand the purpose of the study and be willing to adhere to the study
             schedule and procedures described in this protocol.

          -  Subject must be 25-64 years of age (inclusive) on the day of signing consent.

          -  Subject must be diagnosed with rheumatoid arthritis as defined by the American College
             of Rheumatology.

          -  Subject must be on stable regimen for treatment of rheumatoid arthritis for a minimum
             of 90 days prior to study start.

          -  Subject must report a wake time after sleep onset (WASO) of greater than or equal to
             45 minutes and less than or equal to 6.5 hours of total sleep time at least three
             times a week over the previous month and symptoms of insomnia must post date onset of
             rheumatoid arthritis.

          -  Subject physical exam must show no clinically significant abnormal findings (other
             than those related to rheumatoid arthritis) at screening.

          -  Subject must have no clinically significant abnormal laboratory findings at screening
             (other than those related to rheumatoid arthritis).

          -  Subject must have no clinically significant ECG abnormalities at screening.

        Exclusion Criteria

          -  Subject has diagnosis of fibromyalgia, or juvenile rheumatoid arthritis.

          -  Subject has history of circadian rhythm disorder, or travels across &gt;3 time zones on a
             regular basis.

          -  Female subject is pregnant, lactating or within 6-months post partum.

          -  Subject has a history of drug or alcohol abuse or dependence in the past 2 years or
             positive urine drug test at screening.

          -  Subject has clinically significant unstable medical abnormality or unstable chronic
             disease (other than insomnia and rheumatoid arthritis) including severe cardiac,
             renal, or hepatic or respiratory disease, seizure disorder.

          -  Subject has participated in any investigational drug study within 30 days prior to
             screening or plans to participate in any investigational drug study during
             participation in this study.

          -  Subject has a history of malignancy within 5 years, or current malignancy, except for
             non-melanoma skin cancer.

          -  Subject has a current primary psychiatric diagnosis of any of the following disorders:
             dementia, delirium, schizophrenia, psychosis, other psychotic disorders, dysthymic
             disorder; major depressive disorder, bipolar disorders; cyclothymic disorder, other
             mood disorders, primary anxiety disorders, primary panic disorders, or any nocturnal
             panic disorder.

          -  Subject has any of the following Personality Disorders diagnoses: schizotypal,
             schizoid, borderline personality disorder; or any other personality disorder that
             would compromise the investigator's ability to evaluate the safety and efficacy of the
             study medication.

          -  Subject has difficulties in sleep initiation or maintenance associated with known
             medical diagnosis [e.g. sleep apnea]; diagnosed and untreated restless leg syndrome
             (RLS) or periodic leg movement syndrome (PLMS).

          -  Subject has used any drugs known or suspected to affect hepatic or renal clearance
             capacity within a period of 30 days prior to screening.

          -  Subject reports consumption of more than two alcoholic beverages daily, 14 or more
             alcoholic beverages weekly, or five or more alcoholic beverages on any given day.

          -  Subject is a rotating or third/night shift worker.

          -  Subject is a staff member or relative of a staff member.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mayfield Village</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2006</study_first_submitted>
  <study_first_submitted_qc>August 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2006</study_first_posted>
  <last_update_submitted>February 21, 2012</last_update_submitted>
  <last_update_submitted_qc>February 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insomnia related to rheumatoid arthritis (RA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

